Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2GR | ISIN: US4510337086 | Ticker-Symbol: 0JV0
NASDAQ
14.05.25 | 21:59
0,722 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IBIO INC Chart 1 Jahr
5-Tage-Chart
IBIO INC 5-Tage-Chart

Aktuelle News zur IBIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.05.iBio, Inc.: iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model3
02.05.iBio, Inc. - 10-Q, Quarterly Report2
02.05.iBio GAAP EPS of -$0.49 misses by $0.243
02.05.iBio, Inc. - 8-K, Current Report1
02.05.iBio, Inc.: iBio Reports Fiscal Third Quarter 2025 Financial Results122SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress....
► Artikel lesen
IBIO Aktie jetzt für 0€ handeln
29.04.iBio secures $6.2 million through warrant exercise2
29.04.iBio sichert sich 6,2 Millionen US-Dollar durch Optionsscheinausübung1
29.04.iBio, Inc.: iBio Raises $6.2 Million Through Warrant Inducement Transaction91SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered...
► Artikel lesen
22.04.iBio, Inc. - 8-K, Current Report12
22.04.iBio, Inc.: iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio8
07.04.iBio reports promising data on obesity treatment antibody8
07.04.iBio, Inc.: iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline165Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo...
► Artikel lesen
07.04.iBio, Inc. - 8-K, Current Report2
03.03.iBio, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities8
03.03.iBio, Inc. - 8-A12B, Registration of securities3
19.02.iBio, Inc. - 8-K, Current Report 2
10.02.iBio GAAP EPS of -$0.484
10.02.iBio, Inc.: iBio Reports Fiscal Second Quarter 2025 Financial Results235SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress....
► Artikel lesen
10.02.iBio, Inc. - 10-Q, Quarterly Report-
10.02.iBio, Inc. - 8-K, Current Report-
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1